Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conjunctival Neoplasms | 3 | 2024 | 4 | 2.510 |
Why?
|
| Sarcoma, Kaposi | 7 | 2023 | 53 | 2.460 |
Why?
|
| HIV Infections | 20 | 2025 | 5097 | 1.980 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 32 | 1.930 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 2023 | 115 | 1.740 |
Why?
|
| Neoplasms | 8 | 2024 | 147 | 1.730 |
Why?
|
| Papillomavirus Infections | 5 | 2024 | 74 | 0.970 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 131 | 0.940 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 4 | 0.890 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 6 | 0.890 |
Why?
|
| Incidence | 10 | 2025 | 685 | 0.710 |
Why?
|
| Humans | 27 | 2025 | 14537 | 0.660 |
Why?
|
| South Africa | 17 | 2025 | 7596 | 0.610 |
Why?
|
| Female | 18 | 2025 | 9103 | 0.600 |
Why?
|
| Male | 15 | 2025 | 6754 | 0.480 |
Why?
|
| Adult | 12 | 2025 | 5913 | 0.430 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 31 | 0.430 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 14 | 0.410 |
Why?
|
| Registries | 4 | 2025 | 91 | 0.360 |
Why?
|
| Middle Aged | 9 | 2025 | 3601 | 0.350 |
Why?
|
| Seroepidemiologic Studies | 3 | 2024 | 109 | 0.330 |
Why?
|
| Case-Control Studies | 6 | 2024 | 480 | 0.290 |
Why?
|
| Burkitt Lymphoma | 1 | 2025 | 4 | 0.240 |
Why?
|
| Tobacco, Smokeless | 1 | 2024 | 7 | 0.240 |
Why?
|
| Young Adult | 5 | 2025 | 2498 | 0.240 |
Why?
|
| Adolescent | 5 | 2025 | 2985 | 0.230 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2024 | 2 | 0.230 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 7 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 176 | 0.220 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 106 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 198 | 0.210 |
Why?
|
| HIV Seropositivity | 2 | 2023 | 265 | 0.210 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 18 | 0.210 |
Why?
|
| Cohort Studies | 2 | 2022 | 967 | 0.200 |
Why?
|
| Child | 3 | 2025 | 2242 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 284 | 0.190 |
Why?
|
| Alcoholism | 1 | 2021 | 17 | 0.190 |
Why?
|
| Aged | 5 | 2025 | 1740 | 0.190 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 5 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 6 | 0.180 |
Why?
|
| Smoking | 1 | 2021 | 100 | 0.180 |
Why?
|
| Papillomaviridae | 1 | 2021 | 34 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 47 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 2 | 2023 | 551 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1422 | 0.170 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.130 |
Why?
|
| HIV-1 | 1 | 2023 | 1260 | 0.120 |
Why?
|
| Risk Factors | 3 | 2024 | 1475 | 0.120 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 1324 | 0.120 |
Why?
|
| Africa South of the Sahara | 2 | 2024 | 353 | 0.100 |
Why?
|
| Life Style | 2 | 2022 | 86 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2021 | 656 | 0.080 |
Why?
|
| Prevalence | 2 | 2022 | 1192 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2025 | 1748 | 0.070 |
Why?
|
| Infant | 2 | 2025 | 2244 | 0.070 |
Why?
|
| Pregnancy | 2 | 2022 | 1862 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2024 | 1 | 0.060 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 2 | 0.060 |
Why?
|
| Human papillomavirus 18 | 1 | 2024 | 7 | 0.060 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 7 | 0.060 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 4 | 0.060 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 4 | 0.060 |
Why?
|
| Vaginal Neoplasms | 1 | 2024 | 3 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2024 | 52 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2024 | 14 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2024 | 7 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2024 | 122 | 0.060 |
Why?
|
| Epidemics | 1 | 2025 | 65 | 0.060 |
Why?
|
| Alleles | 1 | 2024 | 143 | 0.060 |
Why?
|
| Haplotypes | 1 | 2024 | 125 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 1 | 0.060 |
Why?
|
| Hormones | 1 | 2023 | 9 | 0.060 |
Why?
|
| United States | 1 | 2023 | 132 | 0.050 |
Why?
|
| Health Priorities | 1 | 2024 | 62 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 39 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 10 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 38 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 42 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 43 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 152 | 0.050 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 27 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 21 | 0.050 |
Why?
|
| Parity | 1 | 2021 | 19 | 0.050 |
Why?
|
| Zimbabwe | 1 | 2022 | 120 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2021 | 26 | 0.050 |
Why?
|
| Logistic Models | 1 | 2021 | 254 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 89 | 0.050 |
Why?
|
| Age Distribution | 1 | 2021 | 107 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 133 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 52 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 104 | 0.040 |
Why?
|
| Data Collection | 1 | 2020 | 86 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 370 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 468 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 376 | 0.040 |
Why?
|
| Time Factors | 1 | 2020 | 507 | 0.040 |
Why?
|